United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 25 mg - quetiapine tablets usp are indicated for the treatment of schizophrenia. the efficacy of quetiapine tablets usp in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine tablets usp for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies (14.1 )]. quetiapine tablets usp are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies (14.2 )]. quetiapine tablets usp are indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adult p

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 400 mg - quetiapine is indicated for the treatment of schizophrenia. the efficacy of quetiapine in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). the effectiveness of quetiapine for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies (14.1)]. quetiapine is indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies (14.2)]. quetiapine is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adult patients with bipolar i and bipolar ii disorder [see clinical studie

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - quetiapine fumarate (unii: 2s3pl1b6uj) (quetiapine - unii:bgl0jsy5si) - quetiapine 200 mg - quetiapine tablets are indicated for the treatment of schizophrenia. the efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13-17 years). the effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see clinical studies ( 14.1) ]. quetiapine tablets are indicated for the acute treatment of manic episodes associated with bipolar i disorder, both as monotherapy and as an adjunct to lithium or divalproex. efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [see clinical studies ( 14.2) ]. quetiapine tablets are indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. efficacy was established in two 8-week monotherapy trials in adult pati

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 345.396 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 230.264 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; lactose monohydrate; calcium hydrogen phosphate dihydrate; povidone; titanium dioxide; hypromellose; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 115.132 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; povidone; colloidal anhydrous silica; magnesium stearate; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - quetiapine fumarate, quantity: 28.783 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; magnesium stearate; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; povidone; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - bipolar disorder. adults = maintenance treatment of bipolar i disorder, as monotherapy, or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes. = treatment of depressive episodes associated with bipolar disorder (see dosage and administration). = treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate.,children/adolescents aged 10 to 17 years,= monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia. (adults and adolescents aged 13 to 17 years) = treatment of schizophrenia.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 460 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 345 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; iron oxide black; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - quetiapine fumarate, quantity: 230 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; sodium citrate; magnesium stearate; titanium dioxide; macrogol 400; iron oxide yellow; iron oxide red; polysorbate 80 - quetiapine modified release tablets are indicated for:,bipolar disorder ? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate for the prevention of relapse/recurrence of manic, depressive or mixed episodes ? treatment of depressive episodes associated with bipolar disorder ? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,efficacy of quetiapine modified release tablets in the treatment of bipolar disorder indications was established in part, on the basis of extrapolation from the established effectiveness of quetiapine immediate release tablets.,schizophrenia treatment of schizophrenia, prevention of relapse and maintenance of clinical improvement during continuation therapy,major depressive disorder treatment of recurrent major depressive disorder (mdd) in patients who are intolerant of, or who have an inadequate response to alternative therapies,generalised anxiety disorder treatment of generalised anxiety disorder (gad)